期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 2, 页码 1206-1224出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00926
关键词
-
资金
- Biogen
Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder that leads to permanent disability. The discovery of BIIB091 as a selective, reversible drug provides a potential treatment option for MS.
Multiple Sclerosis is a chronic autoimmune neurodegenerative disorder of the central nervous system (CNS) that is characterized by inflammation, demyelination, and axonal injury leading to permeant disability. In the early stage of MS, inflammation is the primary driver of the disease progression. There remains an unmet need to develop high efficacy therapies with superior safety profiles to prevent the inflammation processes leading to disability. Herein, we describe the discovery of BIIB091, a structurally distinct orthosteric ATP competitive, reversible inhibitor that binds the BTK protein in a DFG-in confirmation designed to sequester Tyr-551, an important phosphorylation site on BTK, into an inactive conformation with excellent affinity. Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据